CCN3 and CCN3 peptides and analogs thereof for therapeutic use
US11505582B2 · kind B2 · utility
1Cited by
2References
7Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 15, 2019 |
| Grant date | Nov 22, 2022 |
| Priority date | — |
| Expiry date | Jul 15, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/475
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.